Teradyne initiated with a Neutral at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Teradyne with a Neutral rating and $110 price target. Teradyne remains a “world-class supplier” of test and robotic technology, but the company is not levered to the right markets for meaningful growth into the 2024 and 2025 time frame after two years of decline, the analyst tells investors in a research note. The firm sees better upside elsewhere in the sector.